The Chemistry, Manufacturing, and Controls (CMC) section of a Premarket Tobacco Product Application (PMTA) remains one of the most misunderstood and underestimated components of the FDA review process for Electronic Nicotine Delivery Systems (ENDS). While toxicology and behavioral data often receive the most attention, CMC deficiencies are among the most common drivers of review delays, information requests, and ultimately marketing denial orders.
This article outlines what FDA is actually evaluating in PMTA CMC submissions, where applicants most often fall short, and how manufacturers can align documentation with regulatory expectations based on real-world review outcomes.
What FDA Means by CMC in a PMTA Context
In the PMTA framework, CMC is not simply a description of how a product is made. FDA uses the CMC section to evaluate whether the product can be consistently manufactured, controlled, and verified to match the product used in nonclinical and clinical testing.
For ENDS products, this evaluation typically spans:
- Product design and component specifications
- Materials of construction and supplier controls
- Manufacturing processes and in-process controls
- Quality systems and documentation practices
- Stability, shelf life, and product evolution controls
The core question FDA is asking is straightforward: Can this applicant reliably make the same product, at scale, over time?
ENDS-Specific CMC Challenges
ENDS products introduce complexities that differ substantially from traditional tobacco products or pharmaceuticals. These include:
- Multi-component assemblies with mechanical, electrical, and chemical interfaces
- Supplier variability for heaters, batteries, and electronic components
- Manufacturing processes that rely on semi-automated or manual steps
- Product performance characteristics that evolve over use, such as coil aging and wicking behavior
FDA expects these realities to be acknowledged and controlled, not ignored.
Common CMC Gaps Observed in PMTA Reviews
Across multiple PMTA programs, several recurring weaknesses appear in CMC submissions:
1. Overreliance on High-Level SOP Descriptions
Applicants frequently submit SOP titles or summaries without demonstrating how procedures are implemented in practice. FDA looks for evidence that procedures are followed, controlled, and verified, not just documented.
2. Incomplete Component Characterization
Critical components such as heating elements, seals, and electrical contacts are often under-specified. Missing details may include material grades, coatings, tolerances, or supplier process controls.
3. Poor Alignment Between Testing and Production
FDA routinely evaluates whether the product tested for aerosol chemistry and toxicology is representative of the product that will be marketed. Any mismatch in materials, suppliers, resistance ranges, or assembly processes raises red flags.
4. Inadequate Change Management
Many submissions fail to describe how design or process changes will be evaluated post-authorization. FDA expects a defined framework for assessing whether changes could impact product performance or exposure.
Manufacturing Controls FDA Actually Cares About
While the level of formality does not need to match pharmaceutical GMPs, FDA does expect ENDS manufacturers to demonstrate control in several key areas:
- Incoming material inspection and acceptance criteria
- Process controls for critical steps such as coil installation and liquid filling
- Verification of resistance, electrical performance, and leak integrity
- Traceability between components, lots, and finished goods
Importantly, FDA does not require perfection, but it does require consistency and justification.
CMC as a Risk-Based Narrative
Strong PMTA CMC sections do not attempt to document everything. Instead, they:
- Identify which attributes are critical to product performance and safety
- Focus controls on those attributes
- Explain why certain variations are acceptable and others are not
This risk-based approach mirrors FDA's internal review logic and helps reviewers understand the applicant's manufacturing philosophy.
Why CMC Often Determines Review Trajectory
In practice, CMC deficiencies tend to cascade. An unclear manufacturing process raises questions about aerosol data. Uncontrolled component variability undermines exposure assessments. Poor change control weakens long-term confidence in the product. As a result, CMC quality often sets the tone for the entire PMTA review.
Final Thoughts
CMC is not a box-checking exercise. For ENDS products, it is the foundation that ties product design, manufacturing, and scientific testing into a coherent regulatory story.
Applicants who treat CMC as an afterthought frequently find themselves responding to extensive deficiency questions. Those who approach it as a strategic component of the PMTA are far more likely to move through review efficiently.
Understanding what FDA is truly evaluating, and aligning documentation accordingly, remains one of the most effective ways to de-risk a PMTA submission.
Need Help with PMTA CMC Requirements?
Navigating PMTA CMC requirements requires both regulatory insight and practical manufacturing experience. If you have questions about aligning your documentation with FDA expectations, we're happy to discuss your specific product and development stage.
Get in Touch